Open Positions (2023)
To kickstart work on our recently approved collaborative research grant TRR355 “Heterogeneity and functional specialization of regulatory T cells in distinct microenvironments” we are looking for two further positions in our lab:
1. A new PhD student in T cell immunology
2. An additional full-time lab technician
Both positions can be taken on starting immediately. Application is open now! Please click the respective links for detailed job descriptions and requirements.
Hertie Network of Excellence (2023)
We are happy to report that the charitable Hertie Foundation has announced today that it will extend the Hertie Network of Excellence in Clinical Neuroscience for another 3 years. Following successful evaluation of the program that supports six leading neuroscientific sites (Tübingen, Berlin, Bonn, Hamburg, Heidelberg-Mannheim and Munich) as well as 24 individual fellows working on transregional and translational projects, an additional 6.5 million Euro will be invested into further promoting the scientific progress of brain research.
New funding (2023)
We are proud to announce that another major collaborative research grant for our group has been approved by the German Research Foundation (DFG): The Transregional Collaborative Research Centre (TRR) 355 – Heterogeneity and functional specialization of regulatory T cells in distinct microenvironments – a joint project by TUM, LMU and University of Mainz. The head of our department, Prof. Korn, will be a co-spokesperson alongside Prof. Ari Waisman from Mainz and Prof. Carolin Daniel at LMU.
In TRR355, we will explore the identity, regulation and relevance of regulatory T cells that remain in the central nervous system (CNS) after acute inflammation has subsided. We will establish how their presence and function is related to prolonged adaptive processes, i.e. local immune regulation, tissue recovery and -dysfunction, using mouse models for multiple sclerosis in conjunction with RNA-seq and ATAC-seq technology as well as targeted gene editing in the CNS. We will soon hire new staff to pursue this project.
Proceedings of the National Academy of Sciences (2022)
Our clinician scientists Dr. Meike Mitsdörffer and Dr. Lilian Aly have just concluded their neuroimmunological assessment of glioblastoma tumors, which we have now published in The Proceedings of the National Academy of Sciences. In close collaboration with Dr. Jens Gempt and his colleagues at the Neurosurgery department, we analyzed the leukocyte infiltrate of resected glioblastoma multiforme (GBM) samples donated by patients to elucidate how its composition could explain the widespread resistance to many immune therapies. By subjecting the isolated infiltrates to bulk RNAseq, flow cytometry and detailed histological analysis, we found distinctive signatures and features of Th17 cell commitment among the CD4 T cells, which could indicate unfavorable adaptive immune responses. Our in-depth characterization of these cells opens up new research avenues for different immune modulation strategies.
Journal of Experimental Medicine (2022)
We have recently published the project of our researchers Christopher Sie and Ravi Kant in the Journal of Experimental Medicine. Based on the work of our former Postdoc Christian Peter, and in collaboration with further colleagues from our group and the TUM, they showed that IL-24, a cytokine expressed by Th17 cells, can have an unexpected cell-intrinsic effect, independent from its secretion and surface receptor engagement. By modulating the release of the transcription factor Stat3 between mitochondrial and nuclear compartments, intracellular IL-24 can help to induce expression of the regulatory cytokine IL-10. This suggests an autoregulatory mechanism in which Th17 cells, upon continuous inflammatory stimuli, begin expressing IL-24, which in turn limits inflammation via secretion of IL-10.
Journal of Molecular Medicine (2022)
The work of our clinician scientist Dr. Ali Afzali has been recently published in the Journal of Molecular Medicine. In this project, Dr. Afzali and colleagues addressed the role of Aquaporin-4 (AQP4) in neuroinflammatory processes during a mouse model disease for multiple sclerosis, i.e. MOG-peptide induced experimental autoimmune encephalomyelitis (EAE). AQP4, a water channel expressed in the retina as well as other organs, and best known as the dominant target antigen in the related disease neuromyelitis optica (NMO), still subserved an important function in EAE, despite not being targeted itself in this model. Using mice with genetically disrupted expression of AQP4, we could show that AQP4 is important to maintain retinal ganglion cell survival, possibly by clearing edematous swelling and preventing maladaptive scarring during and following inflammation.
Hertie Network of Excellence (2022)
The Institute of Experimental Neuroimmunology is proud to announce its membership in the Hertie Network of Excellence in Clinical Neuroscience. The network’s goal is to foster interaction between cutting-edge laboratories in Germany, bringing together clinical and scientific expertise to allow faster translational breakthroughs in the treatment of neurological disorders.
It comprises 6 sites (Tübingen, Berlin, Bonn, Hamburg, Heidelberg-Mannheim and Munich) with highly-decorated universities and researchers. The Hertie Foundation is a charity dedicated to promoting brain research and democracy since 1974.
Watch the introduction video for the Hertie network to learn more about our common goal.
Global Immunotalks (2022)
We have the pleasure of contributing to this year’s global immunotalks, a public lecture series featuring state-of-the-art research presented by a selection of leading international colleagues in the field of immunology. All dates and times for 2022 can be found at the UCSD website. You can join via Zoom and find previous recordings on Youtube. Prof. Korn will report on our findings on tissue imprinting of autoreactive T cells at 6 pm (CET) on February 16.
Nature Immunology (2021)
We have recently published the project of our researcher Michael Hiltensperger. In his work, he demonstrates that the site of T cell priming (gut vs. skin draining lymph nodes) dictate their effector phenotype and homing to distal sites of immunopathology. By site-specific in vivo labeling of antigen-specific T cells in inguinal (i) or gut draining mesenteric (m) lymph nodes, we show that i-T cells and m-T cells isolated from the inflamed central nervous system in a model of multiple sclerosis are distinct. i-T cells infiltrated white and gray matter, while m-T cells were recruited only to white matter.
Brain (2021)
We have recently published the work of our clinical scientist Dr. Meike Mitsdörffer. Using a spontaneous mouse model of multiple sclerosis, she showed that meningeal B cell aggregates, previously considered a detrimental component of the chronic pathogenesis in CNS inflammation, can also have an unexpected regulatory function in the disease course. Dr. Mitsdörffer revealed that the formation of these aggregates is dependent on the alpha4-integrin expression of their constituting lymphocytes. Eliminating the B cell aggregates by antibody- or CAR-T-cell treatment exacerbated the disease symptoms. These findings represent an important caveat when developing targeted treatment strategies in the future.
New & Extended Funding (2020)
We are happy to report that two of our grants, the Transregio TR128 and the CRC1054, have recently been extended for another four years, now entering their third funding periods each. In the TR128, we will continue to elucidate the role of IL-6 in Multiple Sclerosis in collaboration with our partners in Mainz. In the CRC1054, we will now focus on Aqp4-related tolerance mechanisms in models of Neuromyelitis Optica together with several collaborators at the LMU.
Furthermore, our new Transregio TR274 has recently been approved for its first funding period. Here, we will address the role of regulatory T cells within CNS (post-)inflammatory niches in the resolution of adaptive immune responses and tissue regeneration. This Transregio strengthens our cooperation with local institutions (LMU, DZNE, HHZ, MPI) and opens new collaborative avenues towards our colleagues in Göttingen (IMSF, MPI).
New premises & colleagues (2019)
The Institute of Experimental Neuroimmunology has moved to its new premises in Trogerstraße. Remaining on the TUM clinical campus at Klinikum rechts der Isar, we have entered new offices and significantly increased our laboratory space. The research building 514 will serve as our main site until the construction of the new MS research facilities is concluded. To make good use of our new environment, we have recruited our new colleagues Tereza Chadimová and Sofia Tyystjärvi.
Journal of Immunology (2019)
We have recently published the project of our researcher Christopher Sie. In his work, he showed that Dendritic cells, unlike T cells, are largely independent from alpha4 integrin (encoded by Itga4) for their accumulation in the central nervous system during a model disease of Multiple Sclerosis, but do dependent on this surface anchor for their population of the intestinal lamina propria.
Cell Reports (2019)
Our postdoctoral researcher Garima Garg recently identified a Blimp1-dependent pathway that preserves regulatory T cell (Treg) stability in inflamed non-lymphoid tissues. CNS-infiltrating Treg cells maintain their identity due to Blimp1-expression via restriction of Dnmt3a and a resulting hypomethylation of the CNS2 region of the Foxp3 locus. Ablation of Blimp1, in turn, leads to hypermethylation, loss of Foxp3 expression and severe disease.
